 The primary objective of this study is to evaluate if immune-tolerance with Alum-formulated GAD Diamyd, combined with high dose Vitamin D3, may delay or stop the autoimmune process leading to clinical type 1 diabetes diagnosed according to American Diabetes Association criteria in non-diabetic 4-17.99 year old children with ongoing beta-cell autoimmunity as indicated by positive islet autoantibodies. 